Managing Community-Acquired Pneumonia in Adults- Pharmacy Technician

  Price  

  Credits  

This product is currently out of stock and unavailable.


Format
Community-acquired pneumonia (CAP), also known as community-acquired bacterial pneumonia (CABP), is an infection of the lungs that is acquired outside of the hospital setting. Lower respiratory infections including CAP are the leading cause of death from infectious disease in the world. In the US, there were 1.3 million emergency department visits and 49,157 deaths attributed to pneumonia in 2017. When combined with influenza, pneumonia was the eighth leading cause of death in the US. In the elderly, CAP has a higher burden of hospitalization and total cost than heart attack, stroke, and fractures combined. It is linked to 1.5 million hospitalizations in adults each year, with an estimated mortality rate of 6.5% during hospitalization. In October of 2019, the American Thoracic Society, along with the Infectious Diseases Society of America, published an updated guideline on the diagnosis and treatment of adults with CAP. This guideline is the long-awaited update to the 2007 version published by the same groups. This update does not provide recommendations for managing foreign travelers or patients who are immunocompromised (eg, patients receiving cancer chemotherapy, bone marrow transplant recipients, HIV patients, etc). Notable changes to the guideline include the removal of the healthcare-associated pneumonia category, the use of empiric amoxicillin monotherapy for outpatients with no coexisting conditions (eg, chronic, lung, heart, liver, or kidney disease; diabetes, asplenia, malignancy, or alcoholism), and the use of macrolide monotherapy only if local resistance rates are less than 25%. This issue summarizes the causes, risk factors, and current treatment recommendations for CAP in adults. The 2019 guideline was released before the pandemic caused by severe acute respiratory syndrome coronavirus(SARS CoV-2). The guideline and this issue do not include information on managing CAP in patients with coronavirus disease 2019 (COVID-19).

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Tech Drug Therapy

Author
Ann Lloyd
PharmD, BCPS-AQ ID, BCIDP
Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • Name 2 common pathogens that are responsible for causing CAP. Identify patient risk factors that can predispose an individual to CAP.
  • List 3 antibiotics that may be used to treat community acquired pneumonia (CAP) and discuss side effects and appropriate administration for each medication.
  • Describe strategies that can help prevent CAP.

Course Accreditation

  • Activity Type:
    Application
  • CE Broker
    876798
  • Universal Activity Number:
    Pharmacy Technician : 0798-0000-21-191-H01-T
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

Credit for this program is issued by passing the final test hosted at www.RxConsultant.com with a score of 70% or higher.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.